About NeuroGeneces
NeuroGeneces is a private company based in Santa Fe, New Mexico, incorporated in 2021 in Delaware. It has reported $555,000 raised in three offerings on Form D since September 2017. Its chief executive is Karen Crow.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | May 1, 2026 | $425,000of $750K target | 13 | $32,692 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 15, 2018 | Apr 19, 2018 | $0target not set | 1 | $0 | Equity, Options, Securities on exerciseRule 504, Rule 506(b) | Form D ↗ |
| Jan 1, 2018 | Sep 11, 2017amended Jan 28, 2019 | $130,000of $1.0M target | 4 | $32,500 | Equity, Debt, Options, Securities on exerciseRule 504, Rule 506(b), 4a5 | Form D/A ↗1 earlier filing |
| Total, three offerings | $555,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on NeuroGeneces's Form D filed May 1, 2026.
KC
BW
Barry Worchel
Executive officer and director